Deficiencies of blood cells (cytopenias) are a major cause of morbidity following chemotherapy, transplantation, in genetic disorders, and of mortality following acute accidental radiation exposures. Therapeutics which are oral are needed to stimulate hematopoietic recovery from radiation-induced marrow damage, increase survival from radiation exposure in disaster conditions, and reduce infections and bleeding in other cytopenias.
Phoenicia scientists have discovered a panel of small molecules (HemokinesTM) that stimulate hematopoiesis in human progenitor cultures, in multi-lineage-hematopoietic cell lines, and in 3 species (including irradiated mice, dogs, and baboons) with oral dosing. With the studies already completed, the selected candidate can be launched in a clinical IND within one year.
- Supported by the Heart, Lung and Blood Institute, and the National Institute of Diabetes, Digestive and Kidney Disorders